Enfuvirtide: A review of its use in the management of HIV infection

Drugs

Volumn 65, Issue 8, 2005, Pages 1139-1160

  Oldfield, Vicki ^a   Keating, Gillian M ^a   Plosker, Greg ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; AMDOXOVIR; AMINOTRANSFERASE; AMPRENAVIR; AMPRENAVIR PHOSPHATE; ANCRIVIROC; ANTIINFECTIVE AGENT; ANTIRETROVIRUS AGENT; ATAZANAVIR; CD4 ANTIGEN; CD4 IMMUNOGLOBULIN G2; CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CXCR4; CYCLOTRIAZADISULFONAMIDE; CYTOCHROME P450; CYTOCHROME P450 1A2; CYTOCHROME P450 2C19; CYTOCHROME P450 2D6; CYTOCHROME P450 2E1; CYTOCHROME P450 3A4; DARUNAVIR; DELAVIRDINE; DIDANOSINE; EFAVIRENZ; EMTRICITABINE; ENFUVIRTIDE; INDINAVIR; LAMIVUDINE; LOPINAVIR; NELFINAVIR; NEVIRAPINE; RITONAVIR; STAVUDINE; TENOFOVIR DISOPROXIL; UNCLASSIFIED DRUG; ZALCITABINE; ZIDOVUDINE;

AMINOTRANSFERASE BLOOD LEVEL; ANTIVIRAL ACTIVITY; ANXIETY; APPETITE; AREA UNDER THE CURVE; BLEEDING; BODY COMPOSITION; BRAIN DISEASE; CELLULITIS; CHILL; CLINICAL TRIAL; CONSTIPATION; COUGHING; DEPRESSION; DERMATITIS; DIARRHEA; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG COST; DRUG DISTRIBUTION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENTIATION; DRUG PROTEIN BINDING; DRUG RESISTANCE; DRUG SENSITIVITY; DRUG TOLERABILITY; DRY SKIN; DYSURIA; EDEMA; EOSINOPHILIA; FATIGUE; FEVER; GLOMERULONEPHRITIS; GUILLAIN BARRE SYNDROME; HEADACHE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERSENSITIVITY; HYPOCALCEMIA; HYPOTENSION; IMMUNOMODULATION; INFLUENZA; INJECTION SITE REACTION; INSOMNIA; LYMPHADENOPATHY; MYALGIA; NAUSEA; NEURODERMATITIS; PERIPHERAL NEUROPATHY; PNEUMONIA; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; RASH; REVIEW; RHINOPHARYNGITIS; RIGOR; SIDE EFFECT; SINUSITIS; SKIN BRUISING; SKIN PAPILLOMA; THROMBOCYTOPENIA; THRUSH; TINNITUS; TREATMENT FAILURE; TREATMENT OUTCOME; UPPER RESPIRATORY TRACT INFECTION; VIRUS LOAD; VIRUS REPLICATION; VOMITING; WEIGHT REDUCTION;

HIV ENVELOPE PROTEIN GP41; HIV FUSION INHIBITORS; HIV INFECTIONS; HUMANS; INJECTIONS, SUBCUTANEOUS; PEPTIDE FRAGMENTS;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 20544456150     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-200565080-00007     Document Type: Review

References (116)

1. European guidelines for the clinical management and treatment of HIV-infected adults in Europe. AIDS 2003 Jun; 17 Suppl. 2: 1-26
2. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents [online]. Available from URL: http:// AIDSinfo.nih.gov [Accessed 2004 Dec 15]
3. Fung HB, Guo Y. Enfuvirtide: a fusion inhibitor for the treatment of HIV infection. Clin Ther 2004 Mar; 26 (3): 352-78
4. Patel IH, Zhang X, Nieforth K, et al. Pharmacokineties, pharmacodynamics and drug interaction potential of enfuvirtide. Clin Pharmacokinet 2005; 44 (2): 175-86
5. Dando TM, Perry CM. Enfuvirtide. Drugs 2003; 63 (24): 2755-66; discussion 2767-8
6. Liu S, Lu H, Niu J, et al. Different from the HIV fusion inhibitor C34, the anti-HIV drug fuzeon (T-20) inhibits HIV-1 entry by targeting multiple sites in gp41 and gp120. J Biol Chem 2005 Jan 18; 280 (12): 11259-73
7. Roche Laboratories Inc., Trimeris Inc. Fuzeon™ (enfuvirtide) for injection: complete product information (US) [online]. Available from URL: http://www.rocheusa.com/products/ fuzeon/pi.pdf [Accessed 2003 Apr 1]
8. Wild CT, Shugars DC, Greenwell TK, et al. Peptides corresponding to a predictive alpha-helical domain of human immunodeficiency virus type 1 gp41 are potent inhibitors of virus infection. Proc Natl Acad Sci U S A 1994 Oct 11; 91 (21): 9770-4
9. Sista P, Melby T, Greenberg ML, et al. Characterization of baseline and treatment-emergent resistance to T-20 (enfuvirtide) observed in phase II clinical trials: substitutions in gp41 amino acids 36-45 and enfuvirtide susceptibility of virus isolates [abstract no. 21]. Antiviral Ther 2002 Jun: 7 (2): S16-S17.
10. Plus poster presented at the 11th International HIV Drug Resistance Workshop; 2002 Jul 2-5; Seville
11. Greenberg ML, Sista P, Miralles GD, et al. Enfuvirtide (T-20) and T-1249 resistance: observations from phase II clinical trials of enfuvirtide in combination with oral antiretrovirals and a phase I/II dose-ranging monotherapy trial of T-1249 [abstract no. 128]. Antiviral Ther 2002; 7 Suppl. 1: S140.
12. Plus poster presented at the 11th International HIV Drug Resistance Workshop; 2002 Jul 2-5; Seville
13. Cilliers T, Patience T, Pillay C, et al. Sensitivity of HIV type 1 subtype C isolates to the entry inhibitor T-20. AIDS. Res Hum Retroviruses 2004 May; 20 (5): 477-82
14. Derdeyn CA, Decker JM, Sfakianos JN, et al. Sensitivity of human immunodeficiency virus type 1 to fusion inhibitors targeted to the gp41 first heptad repeat involves distinct regions of gp41 and is consistently modulated by gp120 interactions with the coreceptor. J Virol 2001 Sep; 75 (18): 8605-14
15. Center for Drug Evaluation and Research. US Food and Drug Administration. Application number 21-481. Microbiology Review(s). 2002
16. Sista P, Melby T, Dhingra U, et al. The fusion inhibitors T-20 and T-1249 demonstrate potent in vitro antiviral activity against clade B HIV-1 isolates resistant to reverse transcriptase and protease inhibitors and non-B clades [abstract no. 2]. Antiviral Ther 2001; 6 Suppl. 1: 3-4.
17. Plus poster presented at the 5th International Workshop on HIV Drug Resistance and Treatment Strategies; 2001 Jun 4-8; Scottsdale
18. Greenberg ML, McDanal CB, Stanfield-Oakley SA. Virus sensitivity to T-20 and T-1249 is independent of coreceptor usage [abstract no. 473]. 8th Conference on Retroviruses and Opportunistic Infections; 2001 Feb 4-8; Chicago
19. Ferguson MR, Filizzola MJ, Montes-Walters M, et al. Enfuvirtide (T-20) sensitivity is similar in macrophages and peripheral blood lymphocytes [abstract no. WePeA5668]. 15th International AIDS Conference; 2004 Jul 11-16; Bangkok
20. Barney S, Guthrie K, Davis D, et al. Pentafuside (T20), a novel inhibitor of HIV-1 fusion and infection, is synergistic when used in combination with reverse transcriptase and protease inhibitors in vitro [abstract]. Antiviral Res 1998 Mar; 37 (3): A54
21. Tremblay CL, Poulin DL, Hicks JL, et al. Favorable interactions between enfuvirtide and 1-beta-D-2,6-diaminopurine dioxolane in vitro. Antimicrob Agents Chemother 2003 Nov; 47 (11): 3644-6
22. Nagashima KA, Thompson DAD, Rosenfield SI, et al. Human immunodeficiency virus type 1 entry inhibitors PRO 542 and T-20 are potently synergistic in blocking virus-cell and cell-cell fusion. J Infect Dis 2001; 183: 1121-5
23. Vermeire K, Princen K, Hatse S, et al. CADA, a novel CD4-targeted HIV inhibitor, is synergistic with various anti-HIV drugs in vitro. AIDS 2004 Nov 5; 18 (16): 2115-25
24. Tremblay CL, Giguel F, Kollmann C, et al. Anti-human immunodeficiency virus interactions of SCH-C (SCH 351125), a CCR5 antagonist, with other antiretroviral agents in vitro. Antimicrob Agents Chemother 2002 May; 46 (5): 1336-9
25. Katlama C, Berger D, Bellos N, et al. Efficacy of TMC114/r in 3-class-experienced patients with limited treatment options: 24-week planned interim analysis. Two 96-week multinational dose-finding studies. 12th Conference on Retroviruses and Opportunistic Infections; 2005 Feb 22-25; Boston
26. Rimsky LT, Shugars DC, Matthews TJ. Determinants of human immunodeficiency virus type 1 resistance to gp41-derived inhibitory peptides. J Virol 1998 Feb; 72 (2): 986-93
27. Beausejour Y, Tremblay MJ. Susceptibility of HIV type 1 to the fusion inhibitor T-20 is reduced on insertion of host intercellular adhesion molecule 1 in the virus membrane. J Infect Dis 2004 Sep 1; 190 (5): 894-902
28. Lu J, Sista P, Giguel F, et al. Relative replicative fitness of human immunodeficiency virus type 1 mutants resistant to enfuvirtide (T-20). J Virol 2004 May; 78 (9): 4628-37
29. Lu J, Sista P, Cammack N, et al. Fitness of HIV-1 clinical isolates resistant to T-20 (enfuvirtide) [abstract no. 67]. Antiviral Ther 2002; 7 Suppl. 1: S74.
30. Plus poster presented at the 11th International HIV Drug Resistance Workshop; 2002 Jul 2-5; Seville
31. Reeves JD, Miamidian JL, Biscone MJ, et al. Impact of mutations in the coreceptor binding site on human immunodeficiency virus type 1 fusion, infection, and entry inhibitor sensitivity. J Virol 2004 May; 78 (10): 5476-85
32. Xu L, Hue S, Taylor S, et al. Minimal variation in T-20 binding domain of different HIV-1 subtypes from antiretroviral-naive and -experienced patients. AIDS 2002 Aug 16; 16 (12): 1684-6
33. Roman F, Gonzalez D, Lambert C, et al. Uncommon mutations at residue positions critical for enfuvirtide (T-20) resistance in enfuvirtide-naive patients infected with subtype B and non-B HIV-1 strains. J Acquir Immune Defic Syndr 2003 Jun 1; 33 (2): 134-9
34. Sista PR, Melby T, Davison D, et al. Characterization of determinants of genotypic and phenotypic resistance to enfuvirtide in baseline and on-treatment HIV-1 isolates. AIDS 2004 Sep 3; 18 (13): 1787-94
35. Wei X, Decker JM, Liu H, et al. Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy. Antimicrob Agents Chemother 2002; 46 (6): 1896-905
36. Greenberg ML, Melby T, Sista P, et al. Baseline and on-treatment susceptibility to enfuvirtide seen in TORO 1 and TORO 2 through 24 weeks [abstract no. 141 plus oral presentation]. 10th Conference on Retroviruses and Opportunistic Infections; 2003 Feb 10-14; Boston
37. Xu L, Pozniak A, Wildfire A, et al. Evolution of HR1 and HR2 mutations in HIV-1 gp41 associated with long-term enfuvirtide therapy. 11th Conference on Retroviruses and Opportunistic Infections; 2004 Feb 8-11; San Francisco
38. Loutfy MR, Montaner JSG, Raboud JM, et al. Genotypic resistance assay for entire gp-41 sequence with identification of gp-41 polymorphisms in enfuvirtide-naive patients and new gp-41 mutations in patients failing enfuvirtide [abstract no. WeOrB 1292]. 15th International AIDS Conference; 2004 Jul 11-16; Bangkok
39. Mink M, Greenberg M, Mosier S, et al. Impact of HIV-1 gp41 amino acid substitutions (positions 36-45) on susceptibility to T-20 (enfuvirtide) in vitro: analysis of primary virus isolates recovered from patients during chronic enfuvirtide treatment and site-directed mutants in NL4-3 [abstract no. 22]. Antiviral Ther 2002 Jun; 7 (2): S17-S18.
40. Plus poster presented at the 11th International HIV Drug Resistance Workshop; 2002 Jul 2-5; Seville
41. Marcelin AG, Reynes J, Yerly S, et al. Characterization of genotypic determinants in HR-1 and HR-2 gp41 domains in individuals with persistent HIV viraemia under T-20. AIDS 2004; 18 (9): 1340-2
42. Poveda E, Rodes B, Lebel-Binay S, et al. Dynamics of enfuvirtide resistance in HIV+ patients during and after long-term enfuvirtide salvage therapy [abstract no. H-190]. 44th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2004 Oct 30-Nov 2; Washington, DC
43. Miralles GD, Melby T, DeMasi R, et al. Withdrawal of fusion inhibitors from a failing antiretroviral regimen results in reversion to enfuvirtide susceptibility [abstract]. Antiviral Ther 2004 Aug; 9(4): S12
44. Melby T, Sista P, Nelson E, et al. Virological characterization of patients through 48 weeks in T20-205 who acquired T-20 (enfuvirtide) resistance-associated mutations during prior short-term enfuvirtide monotherapy [abstract no. 70]. Antiviral Ther 2002; 7 Suppl. 1: S77.
45. Plus poster presented at the 11th International HIV Drug Resistance Workshop; 2002 Jul 2-5; Seville
46. Barretina J, Blanco J, Bonjoch A, et al. Immunological and virological study of enfuvirtide-treated HIV-positive patients. AIDS 2004 Aug 20; 18 (12): 1673-82
47. Wat C, Pantaleo G, Herath D, et al. Incidence of baseline (BL) elevated serum IgE levels in HIV-treatment-experienced population of TORO studies remains stable during treatment and does not correlate to enfuvirtide (ENF) use [abstract]. 44th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2004 Oct 30-Nov 2; Washington, DC
48. Walmsley S, Henry K, Katlama C, et al. Lack of influence of gp41 antibodies that cross-react with enfuvirtide on the efficacy and safety of enfuvirtide in TORO 1. and TORO 2 phase III trials [abstract no. 558]. 10th Conference on Retroviruses and Opportunistic Infections; 2003 Feb 10-14; Boston
49. Zhang X, Nieforth K, Lang JM, et al. Pharmacokinetics of plasma enfuvirtide after subcutaneous administration to patients with human immunodeficiency virus: inverse gaussian density absorption and 2-compartment disposition. Clin Pharmacol Ther 2002 Jul; 72 (1): 10-9
50. Thompson M, True A, Chiu Y, et al. Pharmacokinetic (PK), pharmacodynamic and safety assessment of QD versus BID dosing with enfuvirtide (ENF) in HIV-infected subjects. 44th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2004 Oct 30-Nov 2; Washington, DC
51. Bellibas SE, Siddique Z, Dorr A, et al. Pharmacokinetics of enfuvirtide in pediatric human immunodeficiency virus 1-infected patients receiving combination therapy. Pediatr Infect Dis J 2004 Dec; 23 (12): 1137-41
52. Kilby JM, Lalezari JP, Eron JJ, et al. The safety, plasma pharmacokinetics, and antiviral activity of subcutaneous enfuvirtide (T-20), a peptide inhibitor of gp41-mediated virus fusion, in HIV-infected adults [published erratum appears in AIDS Res Hum Retroviruses 2003 Jan 1; 19 (1): 83]. AIDS Res Hum Retroviruses 2002 Jul 1; 18 (10): 685-93
53. Bonora S, de Requena DG, Castagna A, et al. Pharmacokinetic and pharmacodynamic determinants of virological response to enfuvirtide-based regimens [poster no. 643]. 12th Conference on Retroviruses and Opportunistic Infections; 2005 Feb 22-25; Boston
54. Soy D, Aweeka FT, Church JA, et al. Population pharmacokinetics of enfuvirtide in pediatric patients with human immunodeficiency virus: searching for exposure-response relationships. Clin Pharmacol Ther 2003 Dec; 74 (6): 569-80
55. Zhang X, Dorr A, Siddique Z, et al. Pharmacokinetics and pharmacodynamics of enfuvirtide in HIV-1 infected adolescents over 24 weeks of treatment [abstract]. Clin Pharmacol Ther 2004 Feb; 75 (2): 26
56. Lalezari JP, Patel IH, Zhang X, et al. Influence of subcutaneous injection site on the steady-state pharmacokinetics of enfuvirtide (T-20) in HIV-1-infected patients. J Clin Virol 2003 Oct; 28 (2): 217-22
57. Ghosn J, Chaix ML, Peytavin G, et al. Penetration of enfuvirtide, tenofovir, efavirenz, and protease inhibitors in the genital tract of HIV-1-infected men. AIDS 2004 Sep 24; 18 (14): 1958-61
58. Zhang X, Lalezari JP, Badley AD, et al. Assessment of drug-drug interaction potential of enfuvirtide in human immunodeficiency virus type 1-infected patients. Clin Pharmacol Ther 2004 Jun; 75 (6): 558-68
59. Ruxrungtham K, Boyd M, Bellibas SE, et al. Lack of interaction between enfuvirtide and ritonavir or ritonavir-boosted saquinavir in HIV-1-infected patients. J Clin Pharmacol 2004 Jul; 44 (7): 793-802
60. Boyd MA, Zhang K, Dorr A, et al. Lack of enzyme-inducing effect of rifampicin on the pharmacokinetics of enfuvirtide. J Clin Pharmacol 2003 Dec; 43 (12): 1382-91
61. Lalezari JP, Henry K, O'Hearn M, et al. Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America: TORO 1 Study Group [published erratum appears in N Engl J Med 2003 Sep 11; 349 (11): 1100]. N Engl J Med 2003 May 29; 348 (22): 2175-85
62. Lazzarin A, Clotet B, Cooper D, et al. Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia: TORO 2 Study Group. N Engl J Med 2003 May 29; 348 (22): 2186-95
63. Cooper D, Hicks C, Cahn P, et al. 24-Week RESIST study analyses: the efficacy of tipranavir/ritonavir (TPV/r) is superior to lopinavir/ritonavir (LPV/r), and the TPV/r treatment response is enhanced by inclusion of genotypically active antiretrovirals in the optimised background regimen (OBR) [poster no. 560]. 12th Conference on Retroviruses and Opportunistic Infections; 2005 Feb 22-25; Boston
64. Church JA, Cunningham C, Hughes M, et al. Safety and antiretroviral activity of chronic subcutaneous administration of T-20 in human immunodeficiency virus 1-infected children. PACTG P1005 Study Team. Pediatr Infect Dis J 2002 Jul; 21 (7): 653-9
65. Church JA, Hughes M, Chen J, et al. Long term tolerability and safety of enfuvirtide for human immunodeficiency virus 1-infected children. Pediatr Infect Dis J 2004 Aug; 23 (8): 713-8
66. Wiznia C, Church J, Emmanuel P, et al. 24-Week safety and efficacy of enfuvirtide as part of an optimised antiretroviral regimen in children [poster R-124]. 12th Conference on Retroviruses and Opportunistic Infections; 2005 Feb 22-25; Boston
67. Wiznia A, Church J, Stavola J, et al. 24-Week safety and efficacy of enfuvirtide as part of an optimized antiretroviral regimen in adolescents [abstract no. 929]. 11th Conference on Retroviruses and Opportunistic Infections; 2004 8-11 Feb; San Francisco
68. Katlama C, Arasteh K, Clotet B, et al. Enfuvirtide TORO studies: 48 week results confirm 24 week findings [abstract no. LB2 plus poster plus slide presentation]. 2nd International Aids Society Conference on HIV Pathogenesis and Treatment: Late Breaker Abstracts; 2003 Jul 13-16; Paris, 280-1
69. Arasteh K, Lazzarin A, Clotet B, et al. TORO: 96 week virological and immunological response and safety evaluation of enfuvirtide with an optimized background regimen [abstract no. MoOrB1058 plus oral presentation]. 15th International AIDS Conference; 2004 Jul 11-16; Bangkok
70. Cohen C, Demasi R, Greenberg M, et al. Selection of non-enfuvirtide (ENF) versus ENF-containing regimens leads to higher failure rates and loss of future antiretroviral (ARV) treatment options [abstract]. 44th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2004 Oct 30-Nov 2; Washington, DC
71. Trottier B. Arasteh K, Henry K, et al. Durability of response to enfuvirtide through 48 weeks in the TORO Trials [abstract no. H-835 plus poster]. 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy; 2003 Sep 14-18; Chicago
72. Montaner J, DeMasi R, Delehanty J, et al. Analysis of virological response of enfuvirtide in TORO: implications for patient management [abstract]. Antiviral Ther 2003; 8 Suppl. 1: 212
73. Walmsley S, Clotet B, Cooper D, et al. Efficacy of enfuvirtide in subgroups of patients through 48 weeks of therapy in the TORO Trials [abstract no. 7.3/15 plus poster]. 9th European AIDS Conference and 1st EACS Resistance and Pharmacology Workshop: 2003 Oct 25; Warsaw, 51-2
74. Montaner J, Chung J, Guimaraes D, et al. A treatment staging proposal derived from a post hoc analysis of the 48 week results from the TORO studies [abstract no. TuPeB4483 plus poster]. 15th International AIDS Conference; 2004 Jul 11-16; Bangkok
75. Katlama C, Raffi F, Saag M, et al. Week 12 response as a predictor of week 48 outcome in patients receiving the HIV fusion inhibitor enfuvirtide in the TORO studies [abstract]. 44th Interscience Conferences on Antimicrobial Agents and Chemotherapy; 2004 Oct 30-Nov 2; Washington, DC
76. Hornberger J, Green J. Clinical prognosis of enfuvirtide in combination with an optimized background regimen among categories of baseline CD4+ cell count and HIV antiretroviral resistance [abstract no. 478]. Antiviral Ther 2003; 8 Suppl. 1: S310.
77. Plus poster presented at the 2nd International Aids Society Conference on HIV Pathogenesis and Treatment; 2003 Jul 13-16; Paris
78. Bartlett JA, Salgo M, DeMasi R. Early viral load responses on enfuvirtide in heavily treatment-experienced patients [abstract no. TuPeB4484 plus poster]. 15th International AIDS Conference; 2004 Jul 11-16; Bangkok
79. Cohen CJ, Clumeck N, Molina JM, et al. Health-related quality of life with enfuvirtide (ENF; T-20) in combination with an optimized background regimen. J Acquir Immune Defic Syndr 2004 Sep 1; 37 (1): 1140-6
80. Clumeck N, Cohen C.J., Thompson M, et al. Impact of enfuvirtide on health-related quality of life at 48 weeks [poster no. 7.3/ 19]. 9th European AIDS Conference and 1st EACS Resistance and Pharmacology Workshop; 2003 Oct 25-29; Warsaw
81. Cohen C, Green J, Wintfeld N, et al. Patient acceptance with self-injection of enfuvirtide for HIV over 48 weeks of treatment [abstract no. 7.1/1 plus poster]. 9th European AIDS Conference and 1st EACS Resistance and Pharmacology Workshop; 2003 Oct 25-29; Warsaw
82. Cohen C, Hellinger J, Johnson M, et al. Patient acceptance of self-injected enfuvirtide at 8 and 24 weeks. HIV Clin Trials 2003; 4 (5): 347-57
83. Roche Products Limited. Fuzeon [online]. Available from URL: http://www.emc.medicines.org.uk [Accessed 2004 Nov 11]
84. Witek J, Rockstroh J. Donatacci L, et al. Adherence to enfuvirtide and to background antiretroviral therapy over 48 weeks and its impact on treatment efficacy [abstract no. WePeB5822]. 15th International AIDS Conference; 2004 Jul 11-16; Bangkok
85. Clumeck N, Cohen C, Thompson M, et al. Relationship of undetectable viral load, change in CD4 count and enfuvirtide treatment on health-related quality of life [poster P102]. 7th International Congress on Drug Therapy in HIV Infection; 2004 Nov 14-18; Glasgow
86. Eron J, Delfraissy J, Kuritzkes D, et al. Safety of enfuvirtide through 48 weeks of therapy in the TORO Trials [abstract no. H-836 plus poster]. 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy; 2003 Sep 14-17; Chicago
87. Lalezari JP, DeJesus E, Northfelt DW, et al. A controlled phase II trial assessing three doses of enfuvirtide (T-20) in combination with abacavir, amprenavir, ritonavir and efavirenz in non-nucleoside reverse transcriptase inhibitor-naive HIV-infected adults. Antiviral Ther 2003 Aug; 8 (4): 279-87
88. Cooper D. An analysis of the correlation between the severity of injection site reactions and the amount of subcutaneous fat in the ALLIANCE cohort [poster no. N-167]. 12th Conference on Retroviruses and Opportunistic Infections; 2005 Feb 22-25; Boston
89. Goodly J, Capuano G, Dolker M, et al. Enfuvirtide experience in the US early access program [abstract no. TuPeB4559 plus poster]. 15th International AIDS Conference; 2004 Jul 11-16; Bangkok
90. Cooper DA, Reiss P, Henry K, et al. The effects of enfuvirtide therapy on body composition and serum lipids through 48 weeks in the TORO trials [poster no. 715]. 11th Conference on Retroviruses and Opportunistic Infections; 2004 Feb 8-11; San Francisco
91. Hornberger JC, Witek J, Kilby JM, et al. Clinical prognosis and cost-effectiveness of enfuvirtide (ENF) in the US [abstract no. H-837 plus poster]. 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy; 2003 Sep 14-17; Chicago, 312
92. Hornberger J, Covington M, Luo R, et al. Integrated economic evaluation of enfuvirtide in the US using a combination of cost-effectiveness analysis and budget impact analysis to enhance health care decision-making [abstract no. CE3]. Value Health 2003; 6 (6): 625
93. Hornberger J, Youle M, Beck EJ, et al. Cost-effectiveness of enfuvirtide from UK health payer perspective [abstract no. 19.5/1 plus poster]. 9th European AIDS Conference and 1st EACS Resistance and Pharmacology Workshop; 2003 Oct 25-29; Warsaw
94. Sax PE, Losina E, Weinstein MC, et al. Cost-effectiveness of a new fusion inhibitor (T-20) for patients who have failed antiretroviral therapy [abstract no. 577]. Antiviral Ther 2003; 8 Suppl. 1: S341
95. Lazzarin A, De Carli C, Giuliani G, et al. Cost-effectiveness of enfuvirtide in Italy based on 48-week data [abstract no. TuPeC4940]. 15th International AIDS Conference; 2004 Jul 11-16; Bangkok
96. Serrano D, Magaz S, Badia X, et al. Cost-effectiveness analysis of Fuzeon added to optimal standard therapy vs. optimized background regimen alone in patients with HIV/AIDS [abstract no. PIN16]. Value Health 2003 Nov 6-2003; 6: 751.
97. Plus poster presented at the 6th International European Congress of the International Society for Pharmacoeconomics and Outcomes; 2003 Nov 9-11; Barcelona
98. Munakata J, Sanders GD, Owens DK, et al. Cost effectiveness of enfuvirtide in the treatment of drug-resistant HIV infection [abstract]. Med Decis Making 2003; 23 (6): 569
99. Williams IG. Enfuvirtide (Fuzeon): the first fusion inhibitor. Int J Clin Pract 2003 Dec; 57 (10): 890-7
100. AIDS epidemic update [online]. Available from URL: http:// www.unaids.org/html/pub/topics/epidemiology/slides02/12-04/epicore2004_dec.html [Accessed 2005 Jan 20]
101. 2004 Report on the global AIDS epidemic: executive summary [online]. Available from URL: http://www.unaids.org/bangkok2004/GAR2004_html/ ExecSummary_en/Execsum_en.pdf [Accessed 2005 Jan 20]
102. Yeni PG, Hammer SM, Hirsch MS, et al. Treatment for adult HIV infection 2004 recommendations of the International AIDS Society - USA panel. JAMA 2004 Jul 14; 292 (2): 251-65
103. Pozniak A, Gazzard B, Anderson J, et al. British HIV Association (BHIVA) guidelines for the treatment of HIV-infected adults with antiretroviral therapy. HIV Med 2003 Oct; 4 Suppl. 1: 1-41
104. Chen RY, Westfall AO, Mugavero MJ, et al. Duration of highly active antiretroviral therapy regimens. Clin Infect Dis 2003 Sep 1; 37: 714-22
105. Steinhart CR. Evaluating the patient for fusion inhibitors. National Aids Drug Assistance Protocol Educational Conference; 2004 May 20-21
106. Guidelines for the use of antiretroviral agents in pediatric HIV infection [online]. Available from URL: http://www.aid-sinfo.nih.gov/guidelines/ pediatric/PED_012004.html [Accessed 2004 Dec 15]
107. Sharland M, Blanche S, Castelli G, et al. PENTA guidelines for the use of antiretroviral therapy, 2004. HIV Med 2004 Jul; 5 Suppl. 2: 61-86
108. Aberg JA, Gallant JE, Anderson J, et al. Primary care guidelines for the management of persons infected with human immunodeficiency virus: recommendations of the HIV Medicine Association of the Infectious Diseases Society of America. Clin Infect Dis 2004 Sep 1; 39: 609-51
109. Paterson DL, Swindells S, Mohr J, et al. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med 2000; 133: 21-30
110. Bangsberg DR, Hecht FM, Charlebois ED, et al. Adherence to protease inhibitors, HIV-1 viral load, and development of drug resistance in an indigent population. AIDS 2000; 14: 357-66
111. Clotet B, Raffi F, Cooper D, et al. Clinical management of treatment-experienced, HIV-infected patients with the fusion inhibitor enfuvirtide: consensus recommendations. AIDS 2004 May 21; 18 (8): 1137-46
112. Varsalone D, Swartz K, Mohammed D. An enfuvirtide empowerment program: do not enter [poster no. P210]. 7th International Congress on Drug Therapy in HIV Infection; 2004 Nov 14-18; Glasgow
113. Sista P, Melby T, Greenberg ML, et al. Subgroup analysis of baseline (BL) susceptibility and early virological response to enfurvitide in the combined TORO studies [abstract]. 12th International HIV Drug Resistance Workshop; 2003 Jun 10-14; Cabo San Lucas
114. Lalezari JP, Bellos N, Richmond G, et al. Final analysis of T1249-102: T-1249 retains potent short term antiviral activity in patients who have failed a regimen containing enfuvirtide [abstract no. H-444]. 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy; 2003 Sep 14-17; Chicago
115. True AL, Zhang Y, Chiu YY, et al. Needle-free administration of enfuvirtide with Biojector 2000 demonstrates bioequivalence to standard needle administration [poster 57]. HIV DART 2004.
116. Frontiers in Development of Antiretroviral Therapy; 2004 Dec 12-16; Montego Bay